Spironolactone for pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests whether spironolactone, a water pill that helps the heart and blood vessels, can improve symptoms in people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It's a phase 2 trial, meaning it's early but may offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of PAH (WHO Group 1) based on a heart catheterization test showing high pressure in the lung arteries.
- If you are on PAH medicines, your dose and symptoms must have been stable for at least 4 weeks.
- You must be 18 years or older.
- You cannot be pregnant or breastfeeding, and must agree to use effective birth control if you could become pregnant.
- Your kidney function must be adequate (eGFR of 35 or higher).
- You must not have taken spironolactone or eplerenone in the last 30 days.
- You must not have severe right heart failure or active infections (like uncontrolled HIV).
- If you have an MRI as part of the study, you must not have any incompatible devices or conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The study aims to see if the drug can improve symptoms and exercise ability.
This study tests a new treatment called sotatercept for people with pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs are narrow, making the heart work harder. The goal is to see if this medicine can help improve symptoms and daily function.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This trial tests a new oral medication, called CS1, that is added to your current PAH medications. The goal is to see if it helps improve your symptoms and ability to exercise.
This trial looks at whether adding spironolactone to your current blood pressure medicines works better for people with primary aldosteronism (a condition where your adrenal glands make too much aldosterone, raising blood pressure). You may qualify if you have this form of high blood pressure but have declined surgery or don't have an adenoma.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.